In this video, Motley Fool health-care bureau chief Brenton Flynn takes a look through some recent SEC filings where investors don't often look for information, to discover some of the less-reported information on some of the biggest names in the health-care investments sector today. He discusses Abbott Labs (NYSE: ABT) and its coming spinoff AbbVie, a new indication for Questcor (NASDAQ: QCOR), a savvy sell by Dendreon (NASDAQ: DNDN), general pessimism about the economic climate from Express Scripts (NASDAQ: ESRX), and some uncertainty from MAKO Surgical (NASDAQ:MAKO) in the wake of Hurricane Sandy.
You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
SEC Sleuth: Abbott Labs, Questcor, Dendreon, Express Scripts, and MAKO Surgical
NYSE: ABT
Abbott Laboratories

Motley Fool analyst Brenton Flynn pours through some recent SEC filings to uncover some interesting info-nuggets.
Brenton Flynn and Max Macaluso have no positions in the stocks mentioned above. The Motley Fool owns shares of Dendreon, Express Scripts, and MAKO Surgical. Motley Fool newsletter services recommend Express Scripts and MAKO Surgical. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Stocks Mentioned



*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Related Articles





Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.